We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05008809
Recruitment Status : Recruiting
First Posted : August 17, 2021
Last Update Posted : July 29, 2022
Sponsor:
Collaborators:
German Research Foundation
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Information provided by (Responsible Party):
Dominik Paul Modest, Charite University, Berlin, Germany

Brief Summary:
This is an open-label, randomized, controlled, multicenter, phase III study with two parallel arms. Patients with metastatic colorectal cancer after definite interventional therapy of all lesions are randomized in a 2:1 fashion (favoring active therapy) to investigate the efficacy, patient reported quality of life and safety of mFOLFOXIRI/mFOLFOX-6 as additive treatment (Arm A) versus active follow-up/surveillance (Arm B).

Condition or disease Intervention/treatment Phase
Colorectal Cancer Drug: mFOLFOX6 Drug: mFOLFOXIRI Phase 3

Detailed Description:

The trial will consist of both a clinical and translational part. During the study, re-assessments (radiologic assessment, blood and QoL) will be conducted for all trial subject of the trial every 3 months. Tumor biopsies will be collected at screening (baseline sample) and in case of relapse of disease if a new tumor sample is obtained.

The objective of the re-assessments is detection of relapse either radiologically or within the translational material (blood samples with ctDNA dynamics and tumor - if available from relapses). CT scans of thorax/abdomen and/or MRI scans will be performed every 3 months within the 2 years after randomization. After the first two relapse-free years, intervals should be stretched to 6 months in the third and following years after study start. Structured follow-up for up to 60 months after randomization should be maintained for both arms.

Patients in Arm A receive additive study drug intervention (mFOLFOXIRI or mFOLFOX-6) for up to six months (12 cycles) after randomization with additional clinical and safety assessments.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 507 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: open-label, randomized, controlled, multicenter, phase III study with two parallel arms
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer Prospective, Randomized, Open, Multicenter Phase III Trial to Investigate the Efficacy of Active Post-resection/Ablation Therapy in Patients With Metastatic Colorectal Cancer
Actual Study Start Date : December 6, 2021
Estimated Primary Completion Date : November 2027
Estimated Study Completion Date : November 2030

Arm Intervention/treatment
Experimental: Treatment
Active treatment with mFOLFOXIRI or mFOLFOX6 q2w up to six months followed by structured Follow-up for up to five years after randomization
Drug: mFOLFOX6
Oxaliplatin: 85 mg/m², 2h IV infusion on d1 Leucovorin: 400 mg/m², 1-2 h IV infusion on d1 5-FU: (optional: 400 mg/m² bolus, 2-5 min IV infusion), 2400 mg/m², 46 h IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles are administered.
Other Name: Leucovorin, Oxaliplatin, 5-fluorouracil (FU)

Drug: mFOLFOXIRI
Oxaliplatin: 85 mg/m², 2h IV infusion on d1 Irinotecan: 150 mg/m², 90 min IV infusion on d1 Leucovorin: 400 mg/m², 1-2 h IV infusion on d1 5-FU: 2400 mg/m², 46 h IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles are administered.
Other Name: Leucovorin, Oxaliplatin, 5-FU, Irinotecan

No Intervention: Control
Structured Follow-up for up to five years after randomization



Primary Outcome Measures :
  1. Progression-free survival (PFS) time [ Time Frame: 24 months ]
    time from randomization to death or evidence of disease relapse/progression (whatever occurs first)


Secondary Outcome Measures :
  1. Overall survival (OS) [ Time Frame: at least 5 years after randomization ]
    time from randomization to the date of death of any cause

  2. Control ol lesions [ Time Frame: up to 5 years after randomization ]
    Local or distant control of lesions according to ablative technique (surgery vs. ablation vs. radiation)

  3. (Serious) Adverse Events [ Time Frame: up to 2 years after randomization ]
    Type, incidence, severity, and causal relationship to active chemotherapy of non-serious adverse events and serious adverse events (severity evaluated according to CTCAE version 5.0)

  4. Quality of life (QoL) [ Time Frame: up to 5 years after randomization ]
    Quality of life (QoL) as assessed with the QoL questionnaire EQ-5D-5L



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patient's signed informed consent.
  2. Patient's age ≥18 years at the time of signing the informed consent.
  3. Histologically confirmed adenocarcinoma of the colon or rectum.
  4. Resected (R0 or R1) and/or effectively treated metastases (all techniques allowed) of colorectal cancer within 3-10 weeks before randomization AND resected primary tumor (synchronous or metachronous).
  5. Absence of significant active wound healing complications (if applicable) prior to randomization. Resolved wound healing complications after resection/ablation are acceptable for inclusion into the trial.
  6. No radiographic evidence of active metastatic disease at study entry in a CT and/or MRI scan not older than 8 weeks. Pre-surgery/ablation images are eligible for the study if all lesions have been addressed in the interval.
  7. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
  8. Adequate bone marrow, hepatic and renal organ function, defined by the following laboratory test results:

    • Absolute neutrophil count ≥ 1.5E+9/L (1500/µL)
    • Hemoglobin ≥ 80 g/L (8 g/dL)
    • Platelet count ≥ 100E+9/L (100000/µL) without transfusion
    • Total serum bilirubin of ≤ 1.5 x upper limit of normal (ULN)
    • Aspartate aminotransferase (AST/GOT) ≤ 3.0 × ULN.
    • Calculated glomerular filtration rate (GFR) according to Cockcroft-Gault formula or according to MDRD ≥ 50 mL/min or serum creatinine ≤ 1.5 x ULN
  9. Patients without anticoagulation need to present with an international normalized ratio (INR) < 1.5 x ULN and prothrombin time (PTT) < 1.5 x ULN. Patient with prophylactic or therapeutic anticoagulation are allowed into the trial.
  10. Proficient fluorouracil metabolism as defined:

    1. Prior treatment with 5-FU or capecitabine without unusual toxicity or
    2. If tested, normal dihydropyrimidine dehydrogenase (DPD) deficiency test according to the standard of the study site or
    3. If tested, in patients with DPD deficiency test with a Clinical Pharmacogenetics Implementation Consortium (CPIC) activity score of 1.0-1.5 fluoropyrimidine dosage should be reduced by 50%
  11. For women of childbearing potential (WOCBP): negative pregnancy test within 14 days before randomization and agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods with a failure rate of < 1% per year during the treatment period and for at least 6 months after the last dose of study treatment.

A woman is considered to be of childbearing potential if she is post-menarcheal, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male partner's sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.

For men: With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for 6 months after the last dose of study treatment. Men must refrain from donating sperm during this same period.

Exclusion Criteria:

  1. Treatment of metastases greater than 3 cm with radio-frequency/microwave ablation within 24 months prior to study entry if applicable.
  2. Treatment of metastases greater than 5 cm with radiation (stereotactic/ brachytherapy) within 24 months prior to study entry if applicable.
  3. Previous chemotherapy for metastatic or localized disease with > 6 cycles of FOLFOX (or FOLFOXIRI) or > 4 cycles of Capecitabine/Oxaliplatin (CAPOX)/XELOX.
  4. New York Heart Association Class III or greater heart failure by clinical judgement.
  5. Myocardial infarction within 6 months prior to randomization; percutaneous transluminal coronary angioplasty (PTCA) with or without stenting within 6 months prior to randomization.
  6. Unstable angina pectoris.
  7. Unstable cardiac arrhythmia > grade 2 NCI CTCAE despite anti-arrhythmic therapy.
  8. Ongoing toxicities > grade 2 NCI CTCAE, in particular peripheral neuropathy.
  9. Active uncontrolled infection by investigator's perspective.
  10. Severe chronic non-healing wounds, ulcerous lesions or untreated bone fracture.
  11. Known hypersensitivity to 5-FU, leucovorin, irinotecan or oxaliplatin or to any of the other excipients listed in section 6.1 of the corresponding Summary of Product Characteristics (SmPC).
  12. Bone marrow depression after radio- or chemotherapy.
  13. Severe kidney dysfunction (creatinine clearance < 30 ml/min) or changes in blood count.
  14. Recent or concomitant treatment with brivudine.
  15. Peripheral sensitive neuropathy with functional impairment (> grade 1 acc. to CTCAE version 5.0 (see appendix)).
  16. Inflammatory bowel disease and/or bowel obstruction.
  17. Simultaneous application of Johannis herbs preparations.
  18. Pernicious or other megaloblastic anaemia caused by vitamin B12 deficiency.
  19. If tested, DPD deficiency test with a CPIC activity score <1.
  20. Major surgical procedure, open biopsy, or significant traumatic injury within 21 days prior to randomization, or abdominal surgery, abdominal interventions or significant abdominal traumatic injury within 21 days prior to randomization or anticipation of need for major surgical procedure during the course of the study or non-recovery from side effects of any such procedure.
  21. Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications.
  22. Medical history of malignant disease other than metastatic colorectal cancer (mCRC) with the following exceptions:

    • patients who have been disease-free for at least three years before randomization
    • patients with adequately treated and completely resected basal cell or squamous cell skin cancer, in situ cervical, breast or prostate cancer, stage I uterine cancer
    • patients with any treated or untreated malignant disease that is associated with a 5-year survival prognosis of ≥ 90% and does not require active therapy
  23. Known alcohol or drug abuse.
  24. Pregnant or breastfeeding females.
  25. Participation in a clinical trial or experimental drug treatment within 28 days prior to potential inclusion in the clinical trial or within a period of 5 half-lives of the substances administered in a clinical trial or during an experimental drug treatment prior to potential inclusion in the clinical trial, depending on which period is longest, or simultaneous participation in another clinical trial while taking part in this clinical trial.
  26. Patients depended on Sponsor, investigator or study site.
  27. Suspected SARS-CoV-2 infection with or without symptoms (evaluation according to local policy in respective center with respect to actual status of pandemic and with reference to the policy that would apply to patients with similar therapy outside the trial). This may include assessment of vaccination status, anamnesis, physical examination and potentially antigen and/or PCR testing.
  28. Patient committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.
  29. Limited legal capacity.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05008809


Contacts
Layout table for location contacts
Contact: Dominik Modest, Prof. Dr. +49 30 450 ext 553222 dominik.modest@charite.de
Contact: Daniel Müller, Dr. +49 69 7601 ext 125 mueller.daniel@ikf-khnw.de

Locations
Show Show 79 study locations
Sponsors and Collaborators
Dominik Paul Modest
German Research Foundation
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Investigators
Layout table for investigator information
Principal Investigator: Dominik Modest, Prof. Dr. Charite University, Berlin, Germany
  Study Documents (Full-Text)

Documents provided by Dominik Paul Modest, Charite University, Berlin, Germany:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Dominik Paul Modest, Prof. Dr. med., Charite University, Berlin, Germany
ClinicalTrials.gov Identifier: NCT05008809    
Other Study ID Numbers: FIRE-9 - PORT
AIO-KRK-0418 ( Other Identifier: AIO )
2020-006144-18 ( EudraCT Number )
First Posted: August 17, 2021    Key Record Dates
Last Update Posted: July 29, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Dominik Paul Modest, Charite University, Berlin, Germany:
Colorectal Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Leucovorin
Fluorouracil
Oxaliplatin
Irinotecan
Levoleucovorin
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Antidotes
Protective Agents
Vitamin B Complex
Vitamins